Valuation: MannKind Corporation

Market Cap 981M 876M 817M 740M 1.39B 93.09B 1.4B 9.78B 3.83B 48.41B 3.68B 3.6B 155B P/E 2026 *
-16.6x
P/E 2027 * 2,440x
Enterprise Value 981M 876M 817M 740M 1.39B 93.09B 1.4B 9.78B 3.83B 48.41B 3.68B 3.6B 155B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 1.95x
Free-Float
98.53%
Yield 2026 *
-
Yield 2027 * -
1 day-2.56%
1 week-17.79%
Current month-21.79%
1 month-18.67%
3 months-24.50%
6 months+15.53%
Current year-46.21%
1 week 3.02
Extreme 3.02
3.53
1 month 3.02
Extreme 3.02
4.22
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 25/05/2017
Director of Finance/CFO 50 22/04/2024
Chief Tech/Sci/R&D Officer - 29/09/2025
Director TitleAgeSince
Director/Board Member 82 01/10/2003
Director/Board Member 82 01/12/2003
Chairman 69 09/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
25/09/26 Sell

Director

-39,051 0.0121%
10/09/26 Sell

Director

-33,558 0.0104%
07/08/26 Sell

Director

-39,051 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
-2.56%-17.79%-40.20%-23.56% 1.01B
-0.32%-5.97%+57.78%+74.48% 70.65B
-1.99%-13.92%+3.01%+51.60% 51.22B
-1.32%-1.70%+6.99%+35.47% 48.04B
-0.58%+0.27%+27.93%+30.76% 43.16B
-2.84%-5.72%+286.54%+530.02% 41.57B
-0.38%-3.78%+6.74%+95.25% 39.84B
-0.39%-1.48%+10.41%+43.19% 30.87B
-7.13%-7.02%-12.99%-14.07% 24.08B
-0.68%-0.48%+18.92%+9.10% 22.2B
Average -1.82%-5.11%+36.51%+83.22% 37.26B
Weighted average by Cap. -1.47%-4.45%+49.23%+101.81%

Financials

2026 *2027 *
Net sales 443M 395M 369M 334M 629M 42.02B 634M 4.42B 1.73B 21.85B 1.66B 1.63B 70.13B 503M 449M 419M 380M 715M 47.75B 720M 5.02B 1.96B 24.83B 1.89B 1.85B 79.69B
Net income -57.7M -51.55M -48.05M -43.56M -81.98M -5.48B -82.62M -576M -225M -2.85B -217M -212M -9.14B 828K 740K 690K 625K 1.18M 78.62M 1.19M 8.26M 3.23M 40.89M 3.11M 3.04M 131M
Net Debt - -
Projected Income Statement - Annual - MannKind Corporation
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
13/10/26 $3.050 -2.56% 4,394,157
12/10/26 $3.130 -4.86% 3,958,086
09/10/26 $3.290 -3.80% 4,549,647
08/10/26 $3.420 -0.87% 4,539,715
07/10/26 $3.450 -7.01% 6,010,062
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - MannKind Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.050USD
Average target price
7.844USD
Spread / Average Target
+157.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MannKind Corporation
  1. Stock Market
  2. Stocks
  3. MNKD Stock